.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .tb-masonry { grid-template-columns: minmax(0, 1fr) minmax(0, 1fr);grid-column-gap: 10px; } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .tb-masonry .tb-brick__content { padding: 0 0 10px 0; } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="95f5751cc2f80f4b7d21b100ff8b624f"] { text-align: left;justify-content: flex-start; } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="40b05292f70a70284b1c1668151484af"] { background: rgba( 250, 246, 246, 1 );padding: 0px;border: 1px solid rgba( 218, 218, 218, 1 ); } .tb-container .tb-container-inner{width:100%;margin:0 auto} .wp-block-toolset-blocks-container.tb-container[data-toolset-blocks-container="15799f218876513e85a62246af23d50a"] { padding: 15px 20px 10px 20px;margin-top: 0px;border: 0px solid rgba( 0, 0, 0, 1 ); } .tb-fields-and-text[data-toolset-blocks-fields-and-text="8d670a655444748b596f1fb0c7115269"] { color: rgba( 0, 0, 0, 1 );margin-bottom: 10px; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="8d670a655444748b596f1fb0c7115269"] p { color: rgba( 0, 0, 0, 1 ); }  .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} .wp-block-image.tb-image[data-toolset-blocks-image="7d618f72fcf8cf3093933d1e4b7feb11"] { max-width: 100%; } .wp-block-image.tb-image[data-toolset-blocks-image="7d618f72fcf8cf3093933d1e4b7feb11"] img { background-color: rgba( 250, 246, 246, 1 );border: 0px solid rgba( 0, 0, 0, 1 ); } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="d38c7b1e6196431e002ed2a380201dca"] .tb-button__link { background-color: rgba( 207, 46, 46, 1 );font-size: 12px;text-transform: capitalize; } .tb-button[data-toolset-blocks-button="d38c7b1e6196431e002ed2a380201dca"] .tb-button__icon { font-family: dashicons; } .tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} .tb-button[data-toolset-blocks-button="d2e2b11f87f20192f81acf521a2702ac"] .tb-button__link { background-color: rgba( 155, 81, 224, 1 );font-size: 12px;text-transform: capitalize; } .tb-button[data-toolset-blocks-button="d2e2b11f87f20192f81acf521a2702ac"] .tb-button__icon { font-family: dashicons; } @media only screen and (max-width: 781px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .tb-masonry { grid-template-columns: minmax(0, 1fr) minmax(0, 1fr);grid-column-gap: 10px; } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .tb-masonry .tb-brick__content { padding: 0 0 10px 0; } .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto} .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} } @media only screen and (max-width: 599px) { .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .tb-masonry { grid-template-columns: minmax(0, 1fr);grid-column-gap: 10px; } .wpv-view-output[data-toolset-views-view-editor="398b1c497a9ce286fa1c53fda77b18cb"] .tb-masonry .tb-brick__content { padding: 0 0 10px 0; } .tb-container .tb-container-inner{width:100%;margin:0 auto}.tb-container .tb-container-inner{width:100%;margin:0 auto} .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em}.tb-button{color:#f1f1f1}.tb-button--left{text-align:left}.tb-button--center{text-align:center}.tb-button--right{text-align:right}.tb-button__link{color:inherit;cursor:pointer;display:inline-block;line-height:100%;text-decoration:none !important;text-align:center;transition:all 0.3s ease}.tb-button__link:hover,.tb-button__link:focus,.tb-button__link:visited{color:inherit}.tb-button__link:hover .tb-button__content,.tb-button__link:focus .tb-button__content,.tb-button__link:visited .tb-button__content{font-family:inherit;font-style:inherit;font-weight:inherit;letter-spacing:inherit;text-decoration:inherit;text-shadow:inherit;text-transform:inherit}.tb-button__content{vertical-align:middle;transition:all 0.3s ease}.tb-button__icon{transition:all 0.3s ease;display:inline-block;vertical-align:middle;font-style:normal !important}.tb-button__icon::before{content:attr(data-font-code);font-weight:normal !important}.tb-button__link{background-color:#444;border-radius:0.3em;font-size:1.3em;margin-bottom:0.76em;padding:0.55em 1.5em 0.55em} } 

New possibility for Lilly erectile drug

September 24, 2012
Sales and Marketing CHMP, Cialis, ED, hyperplasia, lilly

Eli Lilly’s erectile disfunction (ED) brand Cialis has been recommended to treat benign prostatic hyperplasia (BPH) in Europe. If the …

News

Pharma creates non-profit R&D organisation

September 21, 2012
Research and Development, Sales and Marketing Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, GlaxoSmithKline, Johnson & Johnson, Pfizer, R&D, Roche Genentech, Sanofi, TransCelerate BioPharma, biopharma

Ten biopharma companies have formed TransCelerate BioPharma Inc, a not-for-profit organisation using money and personnel from each firm, with a …

News

China sees fresh wave of drug price cuts

September 21, 2012
Manufacturing and Production, Sales and Marketing China, Lunt, NDRC, ageing

China has unveiled yet another round of price cuts to prescription medicines. The price cuts cover more than 200 formulations …

News

Transgene appoints Nathalie Adda as chief medical officer

September 21, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Nathalie Adda, Transgene

Transgene has announced the appointment of Dr Nathalie Adda as chief medical officer. Responsible for medical and regulatory affairs of …

Appointment

Merz Pharma slammed by PMCPA

September 21, 2012
Medical Communications, Sales and Marketing ABPI, Merz Pharma, PMCPA

Merz Pharma UK has been rapped over the knuckles for three of the most serious breaches it is possible to …

News

Almirall’s COPD drug launched in Europe

September 20, 2012
Sales and Marketing Advair, Almirall, Eklira, Genuair, Seretide, Spiriva

Almirall has launched COPD treatment Eklira in Denmark following approval from the European Commission. Phase III trials demonstrated that Eklira …

News

Teva announces appointment of Prof Itzhak Krinsky

September 20, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Itzhak Krinsky, Teva

Teva has announced the appointment of Professor Itzhak Krinsky as chairman of Teva Japan and Teva South Korea and head …

Appointment

Sanofi cleared in sales row

September 20, 2012
Medical Communications, Sales and Marketing ABPI, CDF, Jevtana, PMCPA, Sanofi

Sanofi has been cleared of any wrongdoing after allegations that it had broken multiple clauses in the ABPI Code of …

News

Boehringer submits new lung cancer drug

September 20, 2012
Research and Development, Sales and Marketing Boehringer, NSCLC, Roche, Tarceva, afatinib

Boehringer Ingelheim has filed its new lung cancer drug with the EMA. Afatinib is the latest targeted therapy for lung …

News

Sandra Peterson joins J&J’s executive committee

September 20, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Sandra Peterson

Sandra Peterson will join Johnson & Johnson on 1 December as Group Worldwide chairman and member of the company’s executive …

Appointment

Afinitor’s new UK indication launched

September 20, 2012
Sales and Marketing Afinitor, CHMP, Novartis, breast cancer

Novartis’ cancer drug Afinitor has been made available in the UK for patients with the most common form of advanced …

News

RSA announces new Board members

September 20, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Nick Stephens, RSA executive search

Life sciences executive search and interim management specialists RSA has announced the appointment of Nick Stephens as executive chairman, John …

Appointment

Silence Therapeutics appoints chief medical adviser

September 19, 2012
Business Services, Research and Development, Sales and Marketing Michael Khan, Silence Therapeutics

Silence Therapeutics has announced the appointment of Michael Khan to its board of directors as chief medical adviser. Dr Khan …

Appointment

J&J sets up life science centres

September 19, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, R&D, innovation

Johnson & Johnson is to set up what it calls regional innovation centres in a bid to speed up the …

News

Steven Gillis to join Shire Board of directors

September 19, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, Steven Gillis

Shire has announced that Dr Steven Gillis will join the Board of directors in October this year. On joining the …

Appointment

Salmonson is new chair of CHMP

September 19, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, MPA, Salmonson

Dr Tomas Salmonson has been elected chair of the Committee for Medicinal Products for Human Use (CHMP) for a three-year …

News

Circassia appoints Stewart Sharpe as VP Commercial Operations

September 19, 2012
Medical Communications, Research and Development, Sales and Marketing Circassia, Stewart Sharpe

Speciality biopharma firm Circassia has announced the appointment of Stewart Sharpe to the newly-created position of vice president, Commercial Operations. …

Appointment

Two new appointments at Pharmalink Consulting

September 18, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kevin Webb, Lorcan Flanagan, Pharmalink

Regulatory affairs specialists Pharmalink Consulting has announced two new appointments. Lorcan Flanagan (pictured) joins as European Business Development manager and …

Appointment

Boehringer says it is rolling out ‘fully disposable’ biomanufacturing

September 18, 2012
Manufacturing and Production Boehringer, CMO, GMP, SUSs

Boehringer Ingelheim says it has developed a production platform for biopharmaceuticals that makes full use disposable technologies both upstream and …

News